Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NYSE:ELMD NYSE:INFU NASDAQ:NYXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.85+1.0%$0.94$0.71▼$1.61$53.36M1.28167,208 shs14,833 shsELMDElectromed$24.27-1.7%$23.80$17.73▼$35.56$203.29M0.4780,214 shs21,933 shsINFUInfuSystem$10.13+0.7%$10.01$4.61▼$11.04$206.92M1.79185,963 shs129,733 shsNYXHNyxoah$5.61-1.1%$5.66$4.34▼$11.87$191.08M1.5398,360 shs22,466 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-0.95%-7.01%-12.36%-10.77%-19.81%ELMDElectromed-0.48%+1.56%+3.39%+31.19%+7.77%INFUInfuSystem+2.76%+8.29%-1.57%+67.39%+48.05%NYXHNyxoah-3.32%-3.90%+16.91%-25.20%-40.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.85+1.0%$0.94$0.71▼$1.61$53.36M1.28167,208 shs14,833 shsELMDElectromed$24.27-1.7%$23.80$17.73▼$35.56$203.29M0.4780,214 shs21,933 shsINFUInfuSystem$10.13+0.7%$10.01$4.61▼$11.04$206.92M1.79185,963 shs129,733 shsNYXHNyxoah$5.61-1.1%$5.66$4.34▼$11.87$191.08M1.5398,360 shs22,466 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-0.95%-7.01%-12.36%-10.77%-19.81%ELMDElectromed-0.48%+1.56%+3.39%+31.19%+7.77%INFUInfuSystem+2.76%+8.29%-1.57%+67.39%+48.05%NYXHNyxoah-3.32%-3.90%+16.91%-25.20%-40.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.50547.06% UpsideELMDElectromed 3.50Strong Buy$36.2549.52% UpsideINFUInfuSystem 3.40Buy$13.5032.74% UpsideNYXHNyxoah 2.50Moderate Buy$15.00171.00% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, ELMD, NYXH, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025CTSOCytosorbentsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NYXHNyxoahWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025INFUInfuSystemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025CTSOCytosorbentsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NYXHNyxoahWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025ELMDElectromedZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/22/2025INFUInfuSystemLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.009/16/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/27/2025ELMDElectromedLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.008/27/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.008/27/2025ELMDElectromedLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$36.11M1.48N/AN/A$0.20 per share4.25ELMDElectromed$64M3.17$0.59 per share41.36$5.10 per share4.75INFUInfuSystem$139.89M1.49$0.80 per share12.79$2.47 per share4.12NYXHNyxoah$4.93M38.22N/AN/A$3.60 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$20.72M-$0.17N/AN/AN/A-25.58%-111.97%-29.00%11/6/2025 (Estimated)ELMDElectromed$5.15M$0.8432.33∞N/A11.34%15.71%13.37%N/AINFUInfuSystem$870K$0.23169.4132.81N/A1.12%2.78%1.41%N/ANYXHNyxoah-$64.10M-$2.30N/AN/AN/A-1,541.84%-79.18%-54.92%11/5/2025 (Estimated)Latest CTSO, ELMD, NYXH, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CTSOCytosorbents-$0.06N/AN/AN/A$10.02 millionN/A11/5/2025Q3 2025NYXHNyxoah-$0.60N/AN/AN/AN/AN/A8/18/2025Q2 2025NYXHNyxoah-$0.62-$0.63-$0.01-$0.63$1.33 million$1.58 million8/7/2025Q2 2025CTSOCytosorbents-$0.07-$0.05+$0.02$0.03$9.79 million$9.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents1.242.341.96ELMDElectromedN/A5.104.74INFUInfuSystem0.501.981.59NYXHNyxoah0.292.632.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%ELMDElectromed40.82%INFUInfuSystem71.13%NYXHNyxoahN/AInsider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%ELMDElectromed10.50%INFUInfuSystem11.40%NYXHNyxoah17.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.76 million58.18 millionOptionableELMDElectromed1608.38 million7.36 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableCTSO, ELMD, NYXH, and INFU HeadlinesRecent News About These CompaniesNyxoah (NASDAQ:NYXH) Stock Price Down 3.1% - Should You Sell?October 17, 2025 | marketbeat.comNyxoah's (NYXH) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comNyxoah Shares Rise on First U.S. Commercial Use of Genio SystemOctober 7, 2025 | zacks.comNyxoah implants first U.S. commercial patients with Genio systemOctober 6, 2025 | msn.comUS-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep DisorderOctober 6, 2025 | msn.comNyxoah Announces First U.S. Commercial Patients Implanted with Genio® SystemOctober 6, 2025 | globenewswire.comPublication relating to transparency notificationsOctober 3, 2025 | globenewswire.comNyxoah Expands in the Middle East to Provide Wider Access to GenioOctober 2, 2025 | zacks.comNyxoah Expands Middle East Presence with New CentersSeptember 25, 2025 | tipranks.comNyxoah (NASDAQ:NYXH) Shares Down 3.6% - Time to Sell?September 24, 2025 | marketbeat.comNyxoah Enters Underwriting Agreement for Public OfferingSeptember 23, 2025 | tipranks.comNyxoah Provides an Update on Expanded Middle East PresenceSeptember 23, 2025 | globenewswire.comNyxoah files patent infringement lawsuit against Inspire MedicalSeptember 16, 2025 | msn.comNyxoah Files Patent Lawsuit Against Inspire Medical SystemsSeptember 15, 2025 | tipranks.comNyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.September 15, 2025 | globenewswire.comNyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comNyxoah Announces Change in Voting Rights Stake by CochlearSeptember 9, 2025 | msn.comBenzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About YetSeptember 7, 2025 | benzinga.comNyxoah Announces Transparency Notification on Shareholding ChangesSeptember 6, 2025 | msn.comPublication relating to transparency notificationsSeptember 5, 2025 | globenewswire.comNyxoah Announces Upcoming Investor EventsSeptember 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTSO, ELMD, NYXH, and INFU Company DescriptionsCytosorbents NASDAQ:CTSO$0.85 +0.01 (+0.97%) Closing price 04:00 PM EasternExtended Trading$0.85 0.00 (-0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Electromed NYSE:ELMD$24.27 -0.42 (-1.70%) Closing price 04:00 PM EasternExtended Trading$24.24 -0.02 (-0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.InfuSystem NYSE:INFU$10.13 +0.07 (+0.70%) Closing price 04:00 PM EasternExtended Trading$10.16 +0.03 (+0.35%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Nyxoah NASDAQ:NYXH$5.61 -0.06 (-1.06%) Closing price 04:00 PM EasternExtended Trading$5.58 -0.03 (-0.53%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
